Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

Blaise K Kutala,1,2 Feryel Mouri,1 Corinne Castelnau,1 Valerie Bouton,1 Nathalie Giuily,1 Nathalie Boyer,1 Tarik Asselah,1,2 Patrick Marcellin1,2 1Service d’hépatologie, Hopital Beaujon-APHP, 2INSERM – University of Paris Diderot, Paris, France Background: The combinat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Sofosbuvir hepatitis C virus interferon-free therapies cirrhosis advanced fibrosis Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/845b388a5b6148f2a06ca2a277d9ddee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:845b388a5b6148f2a06ca2a277d9ddee
record_format	dspace
spelling	oai:doaj.org-article:845b388a5b6148f2a06ca2a277d9ddee2021-12-02T01:15:11ZEfficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort1179-1535https://doaj.org/article/845b388a5b6148f2a06ca2a277d9ddee2017-12-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-sofosbuvir-based-therapies-in-patients-with-adv-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Blaise K Kutala,1,2 Feryel Mouri,1 Corinne Castelnau,1 Valerie Bouton,1 Nathalie Giuily,1 Nathalie Boyer,1 Tarik Asselah,1,2 Patrick Marcellin1,2 1Service d’hépatologie, Hopital Beaujon-APHP, 2INSERM – University of Paris Diderot, Paris, France Background: The combination of sofosbuvir (SOF) with ribavirin (RBV) or daclatasvir (DCV) or simeprevir (SIM) for the treatment of patients infected by chronic hepatitis C (CHC) have led to significantly increased rates of sustained virological response (SVR). However, there is only limited data regarding factors associated with treatment failure in a “real-life” cohort. Patients and methods: Consecutive treatment-naive and treatment-experienced patients F3–F4 were treated with SOF-based interferon-free therapy in our hospital from November 2013 to July 2015. The primary endpoint was the proportion of patients with sustained virological response 12 weeks after cessation of therapy (SVR12). Results: A total of 167 treatment-naive and 207 treatment-experienced patients were treated and followed up for 2 years (n=383). Overall, 71% were men; among them, 54% had cirrhosis and the median age was 53 years. SVR12 was achieved by 82% of the patients receiving SOF+RBV, 92% receiving SOF+DCV, and 79% receiving SOF+SIM. Metavir F4 and albumin serum were found as independent risk factors associated with treatment failure in groups receiving SOF+RBV (p=0.008 and p=0.001), SOF+DCV (p=0.038 and p=0.043), and SOF+SIM±RBV (p=0.014 and p=0.017), respectively. The most common adverse events were fatigue, nausea, headache, and anemia. Three patients discontinued the treatment due to an adverse event. Conclusion: These findings suggest that 12-week SOF-based regimen plus RBV or DCV or SIM is an efficacious and well-tolerated treatment in CHC patients with fibrosis stage F3–F4. Patients, who display risk factors for cirrhosis, should be referred to an experienced viral hepatitis center. Keywords: sofosbuvir, hepatitis C virus, interferon-free therapies, cirrhosis, advanced fibrosisKutala BKMouri FCastelnau CBouton VGiuily NBoyer NAsselah TMarcellin PDove Medical PressarticleSofosbuvirhepatitis C virusinterferon-free therapiescirrhosisadvanced fibrosisDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 9, Pp 67-73 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Sofosbuvir hepatitis C virus interferon-free therapies cirrhosis advanced fibrosis Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Sofosbuvir hepatitis C virus interferon-free therapies cirrhosis advanced fibrosis Diseases of the digestive system. Gastroenterology RC799-869 Kutala BK Mouri F Castelnau C Bouton V Giuily N Boyer N Asselah T Marcellin P Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
description	Blaise K Kutala,1,2 Feryel Mouri,1 Corinne Castelnau,1 Valerie Bouton,1 Nathalie Giuily,1 Nathalie Boyer,1 Tarik Asselah,1,2 Patrick Marcellin1,2 1Service d’hépatologie, Hopital Beaujon-APHP, 2INSERM – University of Paris Diderot, Paris, France Background: The combination of sofosbuvir (SOF) with ribavirin (RBV) or daclatasvir (DCV) or simeprevir (SIM) for the treatment of patients infected by chronic hepatitis C (CHC) have led to significantly increased rates of sustained virological response (SVR). However, there is only limited data regarding factors associated with treatment failure in a “real-life” cohort. Patients and methods: Consecutive treatment-naive and treatment-experienced patients F3–F4 were treated with SOF-based interferon-free therapy in our hospital from November 2013 to July 2015. The primary endpoint was the proportion of patients with sustained virological response 12 weeks after cessation of therapy (SVR12). Results: A total of 167 treatment-naive and 207 treatment-experienced patients were treated and followed up for 2 years (n=383). Overall, 71% were men; among them, 54% had cirrhosis and the median age was 53 years. SVR12 was achieved by 82% of the patients receiving SOF+RBV, 92% receiving SOF+DCV, and 79% receiving SOF+SIM. Metavir F4 and albumin serum were found as independent risk factors associated with treatment failure in groups receiving SOF+RBV (p=0.008 and p=0.001), SOF+DCV (p=0.038 and p=0.043), and SOF+SIM±RBV (p=0.014 and p=0.017), respectively. The most common adverse events were fatigue, nausea, headache, and anemia. Three patients discontinued the treatment due to an adverse event. Conclusion: These findings suggest that 12-week SOF-based regimen plus RBV or DCV or SIM is an efficacious and well-tolerated treatment in CHC patients with fibrosis stage F3–F4. Patients, who display risk factors for cirrhosis, should be referred to an experienced viral hepatitis center. Keywords: sofosbuvir, hepatitis C virus, interferon-free therapies, cirrhosis, advanced fibrosis
format	article
author	Kutala BK Mouri F Castelnau C Bouton V Giuily N Boyer N Asselah T Marcellin P
author_facet	Kutala BK Mouri F Castelnau C Bouton V Giuily N Boyer N Asselah T Marcellin P
author_sort	Kutala BK
title	Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
title_short	Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
title_full	Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
title_fullStr	Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
title_full_unstemmed	Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
title_sort	efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/845b388a5b6148f2a06ca2a277d9ddee
work_keys_str_mv	AT kutalabk efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort AT mourif efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort AT castelnauc efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort AT boutonv efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort AT giuilyn efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort AT boyern efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort AT asselaht efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort AT marcellinp efficacyandsafetyofsofosbuvirbasedtherapiesinpatientswithadvancedliverdiseaseinareallifecohort
_version_	1718403210581901312

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

Ejemplares similares